The FDA Has Blood on its Hands? | Balaji Srinivasan

Balaji Srinivasan, an entrepreneur and futurist renowned for his insights on drug approvals and government reform, dives deep into the FDA's contentious role in healthcare. He argues that the FDA hinders innovation, emphasizing the bureaucracy's toll on drug accessibility. Srinivasan shares his reasons for declining a position in Trump’s FDA and critiques the regulatory delays that endanger patient lives, highlighting the need for systemic change. The discussion also touches on Hollywood's flawed portrayals of regulators and the paradox of escalating homelessness funding.